Cargando…
Updates in the Diffuse Large B-Cell Lymphoma Treatment Landscape
During JADPRO Live Virtual 2021, presenters discussed updates in the treatment of diffuse large B-cell lymphoma (DLBCL), including novel agents and chimeric antigen receptor (CAR) T-cell therapy, and how the treatment and management of patients with DLBCL has been affected by the COVID-19 pandemic.
Autores principales: | Ames, Ashley, Lee, Diane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126354/ https://www.ncbi.nlm.nih.gov/pubmed/35663173 http://dx.doi.org/10.6004/jadpro.2022.13.3.33 |
Ejemplares similares
-
T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update
por: Balendran, Shalini, et al.
Publicado: (2023) -
Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping
por: Carvalho, Ana Sofia, et al.
Publicado: (2021) -
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
por: Modi, Dipenkumar, et al.
Publicado: (2021) -
Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations
por: Chan, Jason Yongsheng, et al.
Publicado: (2023) -
Diffuse Large B-Cell Lymphoma of the Cecum
por: Azad, Farhan, et al.
Publicado: (2023)